|
Mitogen-activated protein kinase kinase (also known as MAP2K, MEK, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). MAP2K is classified as . There are seven genes: * (aka MEK1) * (aka MEK2) * (aka MKK3) * (aka MKK4) * (aka MKK5) * (aka MKK6) * (aka MKK7) The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways. The acronym MEK derives from Mitogen/Extracellular signal-regulated Kinase. ==Role in Melanoma== MEK is a member of the MAPK signaling cascade that is activated in melanoma.〔Falchook, Gerald S, Karl D Lewis, Jeffrey R Infante, Michael S Gordon, Nicholas J Vogelzang, Douglas J DeMarini, and Leslie A Fecher, et al. 2012. "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial." The Lancet Oncology 13, no. 8: 782-789.〕 When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Mitogen-activated protein kinase kinase」の詳細全文を読む スポンサード リンク
|